Back to Search Results


Elevated Maternal Serum AFP (MSAFP) During the Second Trimester

Author: Michael T. Mennuti, MD

Editor: Timothy Klatt, MD

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

Alpha-fetoprotein is produced by the fetal liver. Levels rise during the second trimester. Values are expressed as MoMs (multiples of the median) for each specific week of gestation, and values greater than 2.5 MoMs are generally considered elevated. MOMS are typically corrected for maternal weight, race, and diabetes. MSAFP is often elevated when there is an open fetal defect such as spina bifida, anencephaly, or an abdominal wall defect. The median MSAFP is reduced about 25% in women carrying a fetus with Trisomy 21 when compared to pregnancies with a normal chromosomal complement.

Measurement of MSAFP at 16 weeks was initially used to screen for open neural tube defects. Testing between 16- and 18-weeks gestation is preferred as sensitivity is highest.  It is also commonly used as one of the analytes in second trimester serum screening for Trisomy 21. Errors in dating which underestimate the gestational may result in false positive elevations. Multiple gestations also cause elevations of MSAFP. The level of alpha-fetoprotein is much higher in fetal than maternal blood (on the order of 50,000:1), so fetal-to-maternal bleeding can markedly elevate MSAFP.  An association between placental accreta spectrum and unexplained elevated second trimester MSAFP has been reported by numerous investigators. Extremely high MSAFP levels can result from a rare germ cell tumor.

Patients with an elevated MSAFP should be initially evaluated with ultrasonography. If errors in dating are found, the MSAFP result should be reinterpreted using the new gestational age or, when the sample was drawn outside of the appropriate gestational age range (15-20 weeks), the test may need to be redrawn. Elevated levels of MSAFP should prompt careful anatomic evaluation for open defects of the spine or abdominal wall. Intracranial anatomic changes (e.g. “lemon sign”, “banana sign”) associated with spina bifida should be evaluated.  Targeted ultrasonography should also be used to examine the placental attachment to the uterus.  Amniocentesis to measure amniotic fluid AFP may be considered. Many experts believe that improvement in ultrasonography has largely supplanted the value of performing amniocentesis primarily to measure amniotic fluid AFP. Testing for fetal-to-maternal bleeding by Kleihauer-Betke staining may be considered, particularly in Rh negative patients.

An association between elevated MSAFP and low birth weight or poor obstetric outcome has been reported. The value of this association in the management of the patient is limited because of the low sensitivity and low positive predictive value of this finding. There are currently no recommendations to modify pregnancy or delivery management based on finding an unexplained elevated MS-AFP in an otherwise normal pregnancy.

Further Reading:

In: Cunningham F, Leveno KJ, Bloom SL, et al; Prenatal Diagnosis. Williams Obstetrics, 25e New York, NY: McGraw-Hill; . Accessed August 18, 2019.

Original approval June 2010; Revised September 2016; Reaffirmed March 2018; Revised September 2019.


********** Notice Regarding Use ************

The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Back to Search Results